Zeng L et al. First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer. Med. 2024 Mar.
[2]Park K, Haura EB, Leighl NB,et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study[J]. J Clin Oncol. 2021 Oct 20;39(30):3391-3402. [3]Robichaux JP, Le X, Vijayan R...
EGFR 20 外显子插入(exon 20insertion, ex20ins)突变是一类 EGFR 突变的亚型,是 NSCLC 继 EGFR 19 外显子缺失(19-Del)和 21 外显子 L858R 点突变(21-L858R)两大常见突变外EGFR 的第三大突变。约占所有 NSCLC 的 1.8%～3%,约占 EGFR 突变型 NSCLC 的 4%～12%。 EGFR ex20ins 异质性强,迄今为止,...
[1]Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications[J]. Lancet Oncol. 2012 Jan;13(1):e23-31. Epub 2011 Jul 19. Erratum...
首页/癌基因/EGFR/ EXON 20 INSERTION EGFR编码的蛋白是一种跨膜糖蛋白,也是表皮生长因子受体家族中的一员,该家族包括HER1(erbB1,EGFR)、HER2(erbB2,NEU)、HER3(erbB3)及HER4(erbB4),也属于受体酪氨酸激酶家族。EGFR作为细胞表面蛋白可与配体如表皮生长因子(EGF)结合,EGFR可被激活,由单体转化为二聚体以及发...
[5]AssessinganOralEGFRInhibitor,YK-209AinPatientsWhoHaveAdvancedNon-smallCellLungCancerWithEGFR(YK-029A-101)YK-029AasFirst-LineTreatmentVersusPlatinum-BasedChemotherapyforNon-SmallCellLungCancer(NSCLC)WithEGFR exon 20insertionMutations(YK-029A-301)YK-029AinTreatmentSideEffectsandTreatment-ICHGCP...
[5]AssessinganOralEGFRInhibitor,YK-209AinPatientsWhoHaveAdvancedNon-smallCellLungCancerWithEGFR(YK-029A-101) YK-029AasFirst-LineTreatmentVersusPlatinum-BasedChemotherapyforNon-SmallCellLungCancer(NSCLC)WithEGFR exon 20insertionMutations(YK-029A-301) YK-029AinTreatmentSideEffectsandTreatment-ICHGCP...
[5]AssessinganOralEGFRInhibitor,YK-209AinPatientsWhoHaveAdvancedNon-smallCellLungCancerWithEGFR(YK-029A-101) YK-029AasFirst-LineTreatmentVersusPlatinum-BasedChemotherapyforNon-SmallCellLungCancer(NSCLC)WithEGFR exon 20insertionMutations(YK-029A-301) YK-029AinTreatmentSideEffectsandTreatment-ICHGCP编辑...
By comparison, cancers with insertion mutations in exon 20 of eitherorare considerably less sensitive to the currently available tyrosine kinase inhibitors and antibodies targeting these receptors. These exon 20 insertions are structurally distinct from otherandmutations, providing an explanation for this ...
[1] Fang W, et al. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer[J]. BMC cancer, 2019, 19: 1-9. [2] Lung Cancer 162(2021) 154-161. [3] Mengzhao Wang, et al. Lancet Respir Med 2023. https://doi.org/10.1016/S2213-2600(23)00379...